Evidence map›Paper›PMID 24955288›Full record

ArticleJournal of clinical & cellular immunology2012

Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators.

Apostolos Stathopoulos, Chrystel Pretto, Laurent Devillers, Denis Pierre, Florence M Hofman, Alan L Epstein, Hooman Farghadani, Carol A Kruse, Martin R Jadus, Thomas C Chen and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical & cellular immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Photodynamic therapy mediated immune therapy of brain tumors.Neuroimmunology and neuroinflammation · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Apostolos StathopoulosDepartment of Neurosurgery, Arlon Hospital, Arlon, Belgium ; Epitopoietic Research Corporation (ERC), Namur, Belgium ; Department of Neurosurgery, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Chrystel PrettoEpitopoietic Research Corporation (ERC), Namur, Belgium.
Laurent DevillersEpitopoietic Research Corporation (ERC), Namur, Belgium.
Denis PierreEpitopoietic Research Corporation (ERC), Namur, Belgium.
Florence M HofmanDepartment of Pathology, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Alan L EpsteinDepartment of Pathology, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Hooman FarghadaniDepartment of General Surgery, Arlon Hospital, Arlon, Belgium.
Carol A KruseDepartment of Neurosurgery, University of California, Los Angeles, California and the Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA 90095, USA.
Martin R JadusVeterans Affairs Medical Center, Long Beach, CA 90822, box 113, 5901 E7th St. and Chao Cancer Center, University of California, Irvine, Orange CA, USA.
Thomas C ChenEpitopoietic Research Corporation (ERC), Namur, Belgium ; Department of Neurosurgery, University of Southern California, Keck School of Medicine, Los Angeles, California, USA.
Virgil E J C SchijnsEpitopoietic Research Corporation (ERC), Namur, Belgium ; Cell Biology & Immunology Group, Wageningen University, PO Box 338, 6700 AH Wageningen, The Netherlands.
Cliniques du Sud Luxembourg · BE

Funding

Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent GliomasR01CA125244 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LIAU, LINDA M · 2010 to 2014
$2.4M
Optimizing Induction Conditions for Immunotherapeutic CTLR01CA154256 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PRINS, ROBERT M · 2010 to 2014
$1.9M
NCI NIH HHS R01 CA125244NCI NIH HHS R01 CA154256
6 · The paper itself

Abstract

The efficacy of a various immunotherapeutic immunisation strategies for malignant glioma brain cancer was evaluated in the syngeneic CNS-1 Lewis rat glioma model. A prototype glioma cancer vaccine, which was composed of multivalent antigens derived from allogeneic and syngeneic cells and lysates, formed the prototype preparation of antigens. These antigens reflect the autologous antigens derived from the patient's surgically removed tumor tissue, as well as allogeneic antigens form glioma tumor tissue surgically removed from donor patients. This antigen mixture provides a broad spectrum of tumor associated antigens (TAA) and helps to prevent escape of tumor immune surveillance when given as a vaccine. This antigen preparation was administered in a therapeutic setting with distinct single or multiple co-stimulation-favouring immunostimulants and evaluated for inhibition of tumor growth. Our prototype vaccine was able to arrest progression of tumor growth when co-delivered in a specific regimen together with the costimulating multi-TLR agonist, Bacille Calmette Guerin (BCG) and interleukin-2, or with the Toll-Like receptor (TLR) 7/8 activator resiquimod.

Identifiers

PMID24955288
PMCPMC4062195
OpenAlexW2125121095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.